Silo Pharma, Inc. (NasdaqCM: SILO)
Health Care · Biotechnology · US
$2.58
-2.64% today · -72.4% 1Y
Silo Pharma, Inc. (NasdaqCM: SILO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.21M and employs 3 people.
Over the last twelve months the share price has lost 72.4%, trading between 2.58 and 15.15.
Tweenvest scores Silo Pharma, Inc. across four factors: quality 31/100, value 50/100. Its strongest factor is value.
SILO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.21M
- Revenue (TTM)
- $54.08K
- P/E
- —
- EPS
- -5.07
- Dividend yield
- —
- Beta (5Y)
- 0.80
- 52-week high
- $15.15
- 52-week low
- $2.58
- Avg volume (3M)
- —
- Shares outstanding
- 1.59M
- Employees
- 3
- Next earnings
- —
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
- ISIN
- US82711P3001
- Founded
- 2010
- Listed since
- Jan 8, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.70 | +2.02% |
Figures last refreshed Aug 18, 2026.